Clinuvel Pharmaceuticals (ASX:CUV) appointed specialty pharmaceutical firm Diligens Salud, part of the Scienza Group, to market and sell the Scenesse (afamelanotide) therapy in Argentina, according to a Friday filing with the Australian bourse.

The therapy, used to treat patients with erythropoietic protoporphyria, will be facilitated under maned-patient programs, with both parties collaborating on long-term formal marketing authorization, the filing said.

Erythropoietic protoporphyria is a genetic condition characterized by skin sensitivity to sunlight and artificial light.

The company's shares were up almost 1% in recent Friday trade.